Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:50:17.222Z.
Calculation as of: 2026-10-06T18:50:17.222Z.
Quote observation: 2026-10-06T18:49:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa223cd5a0006a47bd3f11d3634c651a1c818c2f8beb58cb941cded2cdd6eca8
PEG RATIO
N/A
Adial Pharmaceuticals, Inc.
Market Cap
$11.19M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.19M | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | N/A |
| BioVie Inc. (BIVI)vs › | $11.09M | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.02M | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.23M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.82M | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.56M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | N/A |
| Pluri Inc. (PLUR)vs › | $10.59M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.57M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
